Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-09-04
2007-09-04
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252060, C514S255050, C514S256000, C514S274000, C514S275000, C514S301000, C514S302000, C514S312000, C514S313000, C514S314000, C514S338000, C514S372000, C514S378000, C514S380000, C544S237000, C544S238000, C544S242000, C544S315000, C544S330000, C544S332000, C544S334000, C544S335000, C544S336000, C544S406000, C544S407000, C544S408000, C544S409000, C544S410000, C546S114000, C546S115000, C546S152000, C546S168000, C546S169000, C546S170000, C546S171000, C546S172000, C546S174000, C546S175000, C546S176000, C546S
Reexamination Certificate
active
10412510
ABSTRACT:
Compounds of formula I:or pharmaceutically acceptable salts thereof, are useful for controlling synaptic transmission in mammals.
REFERENCES:
patent: 5382584 (1995-01-01), Balasubramanian
patent: 5478939 (1995-12-01), Trybulski et al.
patent: 5652258 (1997-07-01), Phillips et al.
patent: 6440970 (2002-08-01), Clark et al.
patent: 6635645 (2003-10-01), Lochead et al.
patent: 0324543 (1989-07-01), None
patent: 0345808 (1989-12-01), None
patent: 0400661 (1990-12-01), None
patent: 2531709 (1984-02-01), None
patent: 9523152 (1995-08-01), None
patent: 9717961 (1997-05-01), None
patent: 9726258 (1997-07-01), None
patent: 9854182 (1998-12-01), None
patent: 9854181 (1999-12-01), None
patent: 0034284 (2000-06-01), None
Arneric, S. P., et al., “Cholinergic channel modulators as a novel therapeutic strategy for Alzheimer's disease”,Exp. Opin. Invest. Drugs, 5(1):79-100 (1996).
Arneric, S. P., et al., “Neuronal Nicotinic Acetylcholine Receptors Novel Targets for Central Nervous System Therapeutics”,Psychopharmacology: The Fourth Generation of Progress, 95-109 (1995).
Bambas, L. L., “Some Chemotherapeutically Active Sulfones”, 67:668-670, 1945.
Barlocco, D., et al., “Mono- and Disubstituted-3,8-diazabicyclo[3.2.1]octane Derivatives as Analgesics Structurally Related to Epibatidine: Synthesis, Activity, and Modeling”,J. Med. Chem., 41:674-681 (1998).
Bouzard, D., et al., “Fluoronaphthyridines and Quinolones as Antibacterial Agents. 2. Synthesis and Structure-Activity Relationships of New 1-tert-Butyl 7-Substituted Derivatives”,J. Med. Chem., 32:1344-1352 (1990).
Ghelardini, C., et al., “Antinociceptive Profile of the New Nicotinic Agonist DBO-83”,Drug Development Research, 40:251-258 (1997).
Hoffman, B. B., et al., “The Autonomic and Somatic Motor Nervous Systems”, Chapter 6-Neurotransmission 105-139, 1996.
Korczyn, A. D., Parkinson's Disease,Psychopharmacology: The Fourth Generation of Progress, 1479-1484 (1995).
Lindstrom, J., “N icotinic Acetylcholine Receptors in Health and Disease”,Molecular Neurobiology, 15:193-222 (1997).
Lloyd, G. K.,et al., “The Potential of Subtype-Selective Neuronal Nicotinic Acetycholine Receptor Agonists as Therapeutic Agents”,Life Sciences, 62(17/18): 1601-1606 (1998).
McGehee, D.S. et al., “Presynaptic ionotropic receptors,” Current Opinion in Neurobiology 6:342-349 (1996).
Rosen, T., et al., “Design, Synthesis, and Properties of (4S)-7-(4-Amino-2-substituted-pyrrolidin-1-yl)quiknolone-3-carboxylic Acids”,J. Med. Chem., 1598-1611 (1988).
Roth, R. H., et al., “Biochemical Pharmacology of Midbrain Dopamine Neurons”,Psychopharmacology: the Fourth Generation of Progress, 227-242 (1995).
Salin-Pascual, R. J., et al., “Antidepressant Effect of Transdermal Nicotine Patches in Nonsmoking Patients with Major Depression”,J. Clin. Psyciatry, 57(9(:387-389 (1996).
Wagaw, S., et al., “The Synthesis of Aminopyridines: A Method Employing Palladium-Catalyzed Carbon-Nitrogen Bond Formation”,J. Org. Chem., 61:7240-7241 (1996).
Williams, M., et al., “Beyond the tobacco debate: dissecting out the therapeutic potential of nicotine”,Exp. Opin. Invest. Drugs, 5(8):1035-1045 (1995).
Wittenberger, S. J., et al., “Dialkyltin Oxide Mediated Addition of Trimethylsilyl Azide to Nitriles. A Novel Preparation of 5-Substituted Tetrazoles”,J. Org. Chem., 58:4139-4141 (1993).
Wonnacott, S., “Presynaptic nicotinic Ach receptors,” TINS 20(2):92-98 (1997).
Bunnelle William H.
Cristina Daniela Barlocco
Daanen Jerome F.
Dart Michael J.
Meyer Michael D.
Abbott Laboratories
Coleman Brenda
Dileo Gabyrleda Ferrari
LandOfFree
Diazabicyclic CNS active agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diazabicyclic CNS active agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diazabicyclic CNS active agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3744625